These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11471479)

  • 1. Potential risks and prevention, Part 1: Fatal adverse drug events.
    Kelly WN
    Am J Health Syst Pharm; 2001 Jul; 58(14):1317-24. PubMed ID: 11471479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential risks and prevention, Part 2: Drug-induced permanent disabilities.
    Kelly WN
    Am J Health Syst Pharm; 2001 Jul; 58(14):1325-9. PubMed ID: 11471480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential risks and prevention, Part 3: Drug-induced threats to life.
    Marcellino K; Kelly WN
    Am J Health Syst Pharm; 2001 Aug; 58(15):1399-405. PubMed ID: 11494784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential risks and prevention, Part 4: Reports of significant adverse drug events.
    Kelly WN
    Am J Health Syst Pharm; 2001 Aug; 58(15):1406-12. PubMed ID: 11494785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database.
    Sonawane KB; Cheng N; Hansen RA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):682-690. PubMed ID: 29952714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports.
    Winterstein AG; Hatton RC; Gonzalez-Rothi R; Johns TE; Segal R
    Am J Health Syst Pharm; 2002 Sep; 59(18):1742-9. PubMed ID: 12298112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.
    Bates DW; Cullen DJ; Laird N; Petersen LA; Small SD; Servi D; Laffel G; Sweitzer BJ; Shea BF; Hallisey R
    JAMA; 1995 Jul; 274(1):29-34. PubMed ID: 7791255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology, comparative methods of detection, and preventability of adverse drug events.
    Al-Tajir GK; Kelly WN
    Ann Pharmacother; 2005; 39(7-8):1169-74. PubMed ID: 15928265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epidemiology of preventable adverse drug events: a review of the literature.
    von Laue NC; Schwappach DL; Koeck CM
    Wien Klin Wochenschr; 2003 Jul; 115(12):407-15. PubMed ID: 12918183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergency department visits caused by adverse drug events: results of a French survey.
    Queneau P; Bannwarth B; Carpentier F; Guliana JM; Bouget J; Trombert B; Leverve X; Lapostolle F; Borron SW; Adnet F;
    Drug Saf; 2007; 30(1):81-8. PubMed ID: 17194173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of medication-related malpractice claims: causes, preventability, and costs.
    Rothschild JM; Federico FA; Gandhi TK; Kaushal R; Williams DH; Bates DW
    Arch Intern Med; 2002 Nov; 162(21):2414-20. PubMed ID: 12437399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical approach to determining costs and frequency of adverse drug events in a health care network.
    Senst BL; Achusim LE; Genest RP; Cosentino LA; Ford CC; Little JA; Raybon SJ; Bates DW
    Am J Health Syst Pharm; 2001 Jun; 58(12):1126-32. PubMed ID: 11449856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detecting adverse drug events during the hospital stay].
    Berga Culleré C; Gorgas Torner MQ; Altimiras Ruiz J; Tuset Creus M; Besalduch Martín M; Capdevila Sunyer M; Torres Gubert M; Casajoana Cortinas MT; Baró Sabaté E; Fernández Solà JR; Moron i Besolí A; Odena Estradé E; Serrais Benavente J; Vitales Farrero MT; Codina Jané C
    Farm Hosp; 2009; 33(6):312-23. PubMed ID: 20038390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for assessing the preventability of adverse drug events: a systematic review.
    Hakkarainen KM; Andersson Sundell K; Petzold M; Hägg S
    Drug Saf; 2012 Feb; 35(2):105-26. PubMed ID: 22201475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for hospital admissions associated with adverse drug events.
    Kongkaew C; Hann M; Mandal J; Williams SD; Metcalfe D; Noyce PR; Ashcroft DM
    Pharmacotherapy; 2013 Aug; 33(8):827-37. PubMed ID: 23686895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug events caused by medication errors in medical inpatients.
    Hardmeier B; Braunschweig S; Cavallaro M; Roos M; Pauli-Magnus C; Giger M; Meier PJ; Fattinger K
    Swiss Med Wkly; 2004 Nov; 134(45-46):664-70. PubMed ID: 15611888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a computer-based adverse-drug-event monitor.
    Hwang SH; Lee S; Koo HK; Kim Y
    Am J Health Syst Pharm; 2008 Dec; 65(23):2265-72. PubMed ID: 19020194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of the adverse drug event trigger tool and the global trigger tool for identifying adverse drug events: experience in a Belgian hospital.
    Carnevali L; Krug B; Amant F; Van Pee D; Gérard V; de Béthune X; Spinewine A
    Ann Pharmacother; 2013 Nov; 47(11):1414-9. PubMed ID: 24285758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The quality of published adverse drug event reports.
    Kelly WN
    Ann Pharmacother; 2003 Dec; 37(12):1774-8. PubMed ID: 14632590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.